Literature DB >> 15075095

Systemic connective tissue disease complicated by Castleman's disease: report of a case and review of the literature.

Ginevra De Marchi1, Salvatore De Vita, Martina Fabris, Cathryn Ann Scott, Gianfranco Ferraccioli.   

Abstract

Castleman's disease is an atypical lymphoproliferative disorder characterized by the prevalence of B CD5-positive cells in the marginal zone. Autoimmune manifestations have often been reported, but the association of Castleman's disease with systemic autoimmune syndromes has been rarely described. However, many authors stress the difficulties in distinguishing between connective tissue disease and Castleman's disease in most cases. To clarify this issue, we describe a patient and review the literature reports of all cases of Castleman's disease associated with a connective tissue disease. A 19-year old woman presented with autoimmune thyroiditis and polymyositis. Seven years after the onset she developed a systemic inflammatory flare and a burst of autoimmunity, followed by generalized lymphoadenopathy. A mediastinal lymph node biopsy led to the diagnosis of Castleman disease of mixed type. Chemotherapy was given, with rapid response of the lymphoproliferative disorder but persistence of the underlying autoimmune disorder. The plasma concentration of B-lymphocyte stimulator (BLyS) was high (13.3 ng/mL) at the diagnosis of Castleman's disease. It fell dramatically after chemotherapy (4.97 ng/mL), even though it remained just above the mean BLyS value found in healthy blood donors (3.37+/-0.78 ng/mL).Castleman's disease can present autoimmune traits. In our patient, Castleman's disease complicated the course of a connective tissue disorder several years after the onset. We hypothesize that chronic stimulation of B-cell clones, particularly CD5+, by BLyS could favor the development of both autoimmune diseases and a broad range of lymphoproliferative disorders (such as Castleman's disease). This is the first report of increased BLyS levels in a patient with Castleman's disease, supporting a possible pathogenetic role of BLyS in the development of an autoimmune disorder and of a B lymphoproliferative disorder years later.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075095

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  12 in total

1.  Sjögren's and plasma cell variant Castleman disease: a case report.

Authors:  Yvonne A Dei-Adomakoh; Leslie Quarcoopome; Afua D Abrahams; Catherine I Segbefia; Dzifa I Dey
Journal:  Ghana Med J       Date:  2018-03

2.  Association of Macrophage Activating Syndrome with Castleman's Syndrome in Systemic Lupus Erythematosus.

Authors:  Shamsa Shariatpanahi; Shahryar Pourfarzam; Mohammadhosein Gheini
Journal:  Iran J Pathol       Date:  2016

3.  Increased CD5-positive polyclonal B cells in Castleman disease: a diagnostic pitfall.

Authors:  Qingyan Liu; Stefania Pittaluga; Theresa Davies-Hill; Mark Raffeld; Liqiang Xi; Elaine S Jaffe
Journal:  Histopathology       Date:  2013-08-19       Impact factor: 5.087

Review 4.  Systemic lupus erythematosus complicated with Castleman disease: a case-based review.

Authors:  Fatma Gül Demirkan; Sümeyra Doğan; Ayşe Kalyoncu Uçar; Hafize Emine Sönmez; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2020-08-14       Impact factor: 2.631

5.  Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases.

Authors:  Dao-Ping Sun; Wen-Ming Chen; Li Wang; Zhen Wang; Jin-Hua Liang; Hua-Yuan Zhu; Lei Fan; Yu-Jie Wu; Wei Xu; Jian-Yong Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

6.  Unicentric castleman's disease located in the lower extremity: a case report.

Authors:  Inga-Marie Schaefer; Harald Günnel; Stefan Schweyer; Michael Korenkov
Journal:  BMC Cancer       Date:  2011-08-12       Impact factor: 4.430

7.  Unicentric mixed variant Castleman disease associated with Hashimoto disease: the role of PET/CT in staging and evaluating response to the treatment.

Authors:  Cengiz Akosman; Nalan Alan Selcuk; Cetin Ordu; Sina Ercan; Isin Dogan Ekici; Basak Oyan
Journal:  Cancer Imaging       Date:  2011-06-15       Impact factor: 3.909

8.  Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital.

Authors:  Jin Mei Luo; Shan Li; Hui Huang; Jian Cao; Kai Xu; Ya Lan Bi; Rui E Feng; Cheng Huang; Ying Zhi Qin; Zuo Jun Xu; Yi Xiao
Journal:  BMC Pulm Med       Date:  2015-04-09       Impact factor: 3.317

Review 9.  Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's Disease.

Authors:  Anne Musters; Amira Assaf; Danielle M Gerlag; Paul P Tak; Sander W Tas
Journal:  Front Immunol       Date:  2015-12-11       Impact factor: 7.561

10.  Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura.

Authors:  Ruchi Sood; Harris C Taylor; Hamed Daw
Journal:  Case Rep Hematol       Date:  2013-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.